Plain-English translation of NCT06218914 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing two experimental treatments — NT-112 and AZD0240 — that are made from your own immune cells that have been specially engineered in a laboratory to recognize and attack cancer cells with a specific KRAS mutation. The study is designed to find safe doses of this medication and see whether it can help people with advanced cancers like lung, colorectal, pancreatic, or endometrial cancer.
Many people with advanced solid cancers have exhausted standard treatment options and have limited hope for a cure. This medication represents a new approach called TCR therapy, which trains the immune system to specifically target cancer cells carrying KRAS mutations — a change found in many hard-to-treat cancers.
You likely qualify if…
You likely don't qualify if…
You would undergo a procedure to collect your own T cells (a type of immune cell), which are then sent to a laboratory to be engineered to recognize your cancer. After the cells are modified, you would receive them back as an infusion. The study involves multiple clinic visits to monitor your health, check how you're responding, and watch for any side effects from the medication.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States